Yuntong Chen,Qingqing Yu,Wenrui Fan,Xianying Zeng,Zibo Zhang,Guobin Tian,Changjun Liu,Hongmei Bao,Longbo Wu,Yanping Zhang,Yongzhen Liu,Suyan Wang,Hongyu Cui,Yulu Duan,Hualan Chen,Yulong Gao

Vet Microbiol.2024 Sep 2:298:110242.doi: 10.1016/j.vetmic.2024.110242. Online ahead of print.

Abstract

The H9N2 subtype of the avian influenza virus (AIV) poses a significant threat to the poultry industry and human health. Recombinant vaccines are the preferred method of controlling H9N2 AIV, and Marek's disease virus (MDV) is the ideal vector for recombinant vaccines. During this study, we constructed two recombinant MDV type 1 strains that carry the hemagglutinin (HA) gene of AIV to provide dual protection against both AIV and MDV. To assess the effects of different MDV insertion sites on the protective efficacy of H9N2 AIV, the HA gene of H9N2 AIV was inserted in UL41 and US2 of the MDV type 1 vector backbone to obtain recombinant viruses rMDV-UL41/HA and rMDV-US2/HA, respectively. An indirect immunofluorescence assay showed sustained expression of HA protein in both recombinant viruses. Additionally, the insertion of the HA gene in UL41 and US2 did not affect MDV replication in cell cultures. After immunization of specific pathogen-free chickens, although both the rMDV-UL41/HA and rMDV-US2/HA groups exhibited similar levels of hemagglutination inhibition antibody titers, only the rMDV-UL41/HA group provided complete protection against the H9N2 AIV challenge, and also offered complete protection against challenge with MDV. These results demonstrated that rMDV-UL41/HA could be used as a promising bivalent vaccine strain against both H9N2 avian influenza and Marek's disease in chickens.

Keywords: H9N2 avian influenza virus; Hemagglutinin protein; MDV1 vaccine strain; Marek’s disease virus; Protective efficacy.